How Does Tesamorelin Work? Mechanism of Action Explained in Plain English

Tesamorelin (Egrifta SV, Egrifta WR) is the only FDA-approved treatment for excess abdominal fat in HIV-positive adults with lipodystrophy. But how does it actually work? The mechanism of action involves the hypothalamus, pituitary gland, growth hormone, and a fat-metabolizing pathway that is disrupted in HIV-associated lipodystrophy. This guide explains the science in plain English.

Step 1: Understanding the Problem — Why HIV Causes Visceral Fat Accumulation

People living with HIV on long-term antiretroviral therapy often develop a condition called HIV-associated lipodystrophy. One key feature of this condition is the accumulation of excess visceral adipose tissue (VAT) — hard, internal belly fat that surrounds the organs inside the abdomen.

Research shows that HIV-positive patients with lipodystrophy have abnormally low levels of growth hormone (GH). GH plays a critical role in regulating fat metabolism — particularly the breakdown of visceral fat. When GH levels are too low, the body's ability to metabolize visceral fat is impaired, and fat accumulates. This is where tesamorelin comes in.

Step 2: What Tesamorelin Is — A Stabilized GHRH Analog

Your hypothalamus (a part of your brain) normally produces a hormone called Growth Hormone-Releasing Hormone (GHRH). GHRH travels to the pituitary gland, a small gland at the base of the brain, and signals it to release growth hormone.

The problem with natural GHRH is that it is rapidly broken down in the bloodstream by an enzyme called dipeptidylaminopeptidase 4 (DPP4) — so quickly that it can't be used as a medication. Tesamorelin solves this problem. It consists of the same 44-amino acid sequence as human GHRH, but with a chemical modification at one end (a hexenoyl group attached to the tyrosine residue at the N-terminus) that makes it resistant to DPP4 degradation. This gives tesamorelin a long enough half-life to work with once-daily dosing.

Step 3: How Tesamorelin Triggers the Pituitary to Release GH

When you inject tesamorelin subcutaneously once daily, it is absorbed into the bloodstream and travels to the pituitary gland. There, it binds to GHRF receptors on specialized pituitary cells called somatotrophs. This binding signals the somatotrophs to synthesize and release growth hormone in pulsatile bursts — mimicking the body's natural pattern of GH secretion.

Critically, tesamorelin works through the body's own regulatory system. It doesn't bypass the normal feedback mechanisms. If IGF-1 levels get too high, the body can partially self-regulate — though medical monitoring is still required.

Step 4: Growth Hormone Increases IGF-1 and Activates Fat Metabolism

The released growth hormone travels to the liver and other tissues, where it stimulates the production of Insulin-like Growth Factor 1 (IGF-1). IGF-1 is one of growth hormone's main messenger molecules. Tesamorelin increases IGF-1 levels by an average of 84% in clinical trials.

Growth hormone itself is both anabolic (builds tissue) and lipolytic (breaks down fat). It acts on adipocytes (fat cells), particularly visceral fat cells, to promote lipolysis — the breakdown of stored fat into fatty acids that can be used for energy. This is how tesamorelin reduces visceral adipose tissue: by restoring growth hormone levels to a range where visceral fat metabolism can function normally.

The Results: What the Clinical Trials Showed

In the pivotal Phase 3 trials that led to FDA approval, tesamorelin at 2 mg per day for 26 weeks produced:

Approximately 15–18% mean reduction in visceral adipose tissue (measured by CT scan)

84% mean increase in IGF-1 levels

Reductions in triglyceride levels — a metabolic benefit associated with visceral fat reduction

No significant weight change overall — tesamorelin is weight neutral

Why Effects Don't Last After Stopping Tesamorelin

Because tesamorelin works by boosting GH levels artificially, its effects are only present while you are taking the medication. When you stop injecting tesamorelin, GH levels fall back to their pre-treatment baseline, IGF-1 drops, and visceral fat begins to re-accumulate. Studies confirm that visceral fat returns toward baseline after discontinuation. This is why most patients who respond to tesamorelin need to continue indefinitely to maintain the fat reduction.

How Tesamorelin Differs from Direct Growth Hormone Replacement

Tesamorelin is not growth hormone. It does not replace GH — it stimulates your own pituitary gland to produce GH. This is an important distinction. Direct GH replacement (somatropin) introduces exogenous hormone into your system, bypassing natural feedback mechanisms and carrying greater risks of side effects like severe insulin resistance and acromegaly (overgrowth of tissues). Tesamorelin's approach is more physiologic — it prompts your pituitary to do what it naturally does, just more effectively.

Now that you understand how tesamorelin works, you may also want to read our overview of what tesamorelin is used for and its full dosing information. If you've been prescribed it and need help finding a pharmacy, medfinder can check specialty pharmacies near you.